Lecithin pp 121-136 | Cite as

Use of Phosphatidylcholine in Brain Diseases: An Overview

  • John H. Growdon
Part of the Advances in Behavioral Biology book series (ABBI, volume 33)


Two biochemical effects of phosphatidylcholine (PC) account for its use in clinical trials treating brain diseases: PC as a precursor for acetylcholine (ACh) biosynthesis, and PC as an integral part of neuronal membranes. This chapter reviews the scientific basis for each postulated use, and describes the results of PC administration to patients with neurological and psychiatric diseases.


Amyotrophic Lateral Sclerosis Tardive Dyskinesia Tourette Syndrome Nuclear Magnetic Resonance Spectroscopy Senile Dementia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alarcon, R.D., Tolbert, L.C., Monti, J.A., Morere, D.A., Walter-Ryan, W.G., Kemp, B., Smythies, J.R., 1985, One-carbon metabolism disturbances in affective disorders. A preliminary report, J. Affective Disord., 9:297–301.CrossRefGoogle Scholar
  2. 2.
    Ailing, C., Gustavsson, L., Kristensson-Aas, A., Wallerstedt, S., 1984, Changes in fatty acid composition of major glycerophospholipids in erythrocyte membranes from chronic alcoholics during withdrawal, Scand. J. Clin. Lab. Invest., 44:283–289.CrossRefGoogle Scholar
  3. 3.
    Ansell, G.B., 1981, The biochemical background to tardive dyskinesia, Neuropharmacology, 4:311–317.CrossRefGoogle Scholar
  4. 4.
    Ansell, G.B., Spanner, S., 1978, The source of choline for acetylcholine synthesis, in: “Cholinergic Mechanisms and Psychopharmacology”, D.J. Jenden, ed., Plenum, New York, pp.431–445.CrossRefGoogle Scholar
  5. 5.
    Aquilonius, S.M., Eckernas, S.A., 1977, Choline therapy in Huntington’s chorea, Neurology, 27:887–889.PubMedCrossRefGoogle Scholar
  6. 6.
    Baldessarini, R.J., Tarsy, D., 1980, Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs, Ann. Rev. Neurosci., 3:23–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Barany, M., Chang, Y.C., Arus, C., Rustan, T., Frey, W.H.II, 1985, Increased glycerol-3-phosphorylcholine in post-mortem Alzheimer’s brain, Lancet i, 517.CrossRefGoogle Scholar
  8. 8.
    Barbeau, A., 1978, Emerging treatments: replacement therapy with choline or lecithin in neurological diseases, Can. J. Neurol. Sci., 1:157–160.Google Scholar
  9. 9.
    Barbeau, A., 1979, Lecithin in movement disorders, in.: “Choline and Lecithin in Brain Disorders”, vol. 5, Nutrition and the Brain, A. Barbeau, J.H. Growdon, R.J. Wurtman, eds., Raven Press, New York, pp. 263–271.Google Scholar
  10. 10.
    Barbeau, A., 1980, Lecithin in Parkinson’s disease, J. Neurol. Transm., 16:187–193.Google Scholar
  11. 11.
    Barbeau, A., 1980, Cholinergic treatment in the Tourette syndrome, N. Engl. J. Med., 302:1310–1311.PubMedCrossRefGoogle Scholar
  12. 12.
    Barbeau, A., Butterworth, R.F., Ngo, T., et al., 1976, Pyruvate metabolism in Friedreich’s ataxia, Can. J. Neurol. Sci., 3:379–388.PubMedGoogle Scholar
  13. 13.
    Barenholz, Y., Yechiel, E., Cohen, R., Deckelbaum, R.J., 1981, Importance of cholesterol-phospholipid interaction in determining dynamics of normal and abetalipoproteinemia red blood cell membrane, Cell Biophys., 3:115–126.PubMedGoogle Scholar
  14. 14.
    Bartus, R.T., Dean, R.L., Goas, J.A., Lippa, A.S., 1980, Age-related changes in passive avoidance retention: modulation with dietary choline, Science, 209:301–303.PubMedCrossRefGoogle Scholar
  15. 15.
    Bierkamper, G.G., Goldberg, A.M., 1980, Release of acetylcholine from the vascular perfused rat phrenic nerve-hemidiaphragm, Brain Res., 202:234–237.PubMedGoogle Scholar
  16. 16.
    Bird, E.D., Iversen, L.L., 1974, Huntington’s chorea: post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia, Brain, 97:457–472.PubMedCrossRefGoogle Scholar
  17. 17.
    Blusztajn, J.K., Wurtman, R.J., 1981, Choline biosynthesis by a preparation enriched in synaptosomes from rat brain, Nature, 290:417–418.PubMedCrossRefGoogle Scholar
  18. 18.
    Blusztajn, J.K., Wurtman, R.J., 1983, Choline and cholinergic neurons, Science, 221:614–620.PubMedCrossRefGoogle Scholar
  19. 19.
    Bondareff, W., Mountjoy, C.Q., Roth, M., 1982, Loss of neurons of origin of the adrenergic projection of cerebral cortex (nucleus locus coeruleus) in senile dementia, Neurology, 32:164–168.PubMedCrossRefGoogle Scholar
  20. 20.
    Branchey, M.H., Branchey, L.B., Bark, N.M., Richardson, M.A., 1979, Lecithin in the treatment of tardive dyskinesia, Commun. Psychopharmacol., 3:303–307.PubMedGoogle Scholar
  21. 21.
    Candy, J.M., Perry, R.H., Perry, E.H., Irving, D., Blessed, G., Fairbairn, A.D., Tomlinson, B.E., 1983, Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases, J. Neurol. Sci., 59:277–289.PubMedCrossRefGoogle Scholar
  22. 22.
    Chamberlain, S., Robinson, N., Walker, J., Smith, C., Benton, S., Kennard, C., Swash, M., Kilkenny, B., Bradbury, S., 1980, Effect of lecithin on disability and plasma free-choline levels in Friedreich’s ataxia, J. Neurol. Neurosurg. Psychiatry, 43:843–845.PubMedCrossRefGoogle Scholar
  23. 23.
    Cohen, B.M., Lipinski, J.F., Altesman, R.I., 1982, Lecithin in the treatment of mania: double-blind, placebo-controlled trials, Am. J. Psychiatry, 139:1162–1164.PubMedGoogle Scholar
  24. 24.
    Cohen, B.M., Miller, A.L., Lipinski, J.F., Pope, H.G., 1980, Lecithin in mania: a preliminary report. Am. J. Psychiatry, 137:242–243.PubMedGoogle Scholar
  25. 25.
    Cohen, E.L., Wurtman, R.J., 1975, Brain acetylcholine: increase after systemic choline administration, Life Sci., 16:1095–1102.PubMedCrossRefGoogle Scholar
  26. 26.
    Cohen E.L., Wurtman, R.J., 1976, Brain acetylcholine: control by dietary choline, Science, 191:561–562.PubMedCrossRefGoogle Scholar
  27. 27.
    Corkin, S., 1981, Brain acetylcholine, aging, and Alzheimer’s disease: implications for treatment, Trends in Neuroscience, 4:287–290.CrossRefGoogle Scholar
  28. 28.
    Corkin, S., Davis, K., Growdon, J., Usdin, E., Wurtman, R., 1982, Alzheimer’s Disease: A Report of Progress in Research, Raven Press, New York.Google Scholar
  29. 29.
    Cornford, E.M., Braun, L.D., Oldendorf, W.H., 1978, Carrier mediated blood-brain barrier transport of choline and certain choline analogs, J. Neurochem., 30: 299–308.PubMedCrossRefGoogle Scholar
  30. 30.
    Davis, K.L., Berger, P.A., Hollister, L.E., 1975, Choline for tardive dyskinesia, N. Engl. J. Med., 293:152.PubMedGoogle Scholar
  31. 31.
    Davis, K.L., Hollister, L.E., Barchas, J.D., et al., 1976, Choline in tardive dyskinesia and Huntington’s disease, Life Sci., 19: 1507–1519.PubMedCrossRefGoogle Scholar
  32. 32.
    Davis, K.L., Hollister, L.E., Berger, P.A., Barchas, J.D., 1975, Cholinergic imbalance hypotheses of psychoses and movement disorders: strategies for evaluation, Psychopharmacol. Commun., 1:533–543.PubMedGoogle Scholar
  33. 33.
    Davis, J.M., 1975, Critique of single amine theories: evidence of a cholinergic influence in the major mental illnesses, Res. Publ. Assoc. Res. Ment. Dis., 54:333–346.Google Scholar
  34. 34.
    Domino, E.F., May, W.W., Demetriou, S., Mathews, B., Tait, S., Kovacic, B., 1985, Lack of clinically significant improvement of patients with tardive dyskinesia following phosphatidylcholine therapy, Biol. Psychiatry, 20:1189–1196.PubMedCrossRefGoogle Scholar
  35. 35.
    Drachman, D.A., 1977, Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology, 27:783–790.PubMedCrossRefGoogle Scholar
  36. 36.
    Fibiger, H.C., Lloyd, K.G., 1984, Neurobiological substrates of tardive dyskinesia: the GABA hypothesis, Trends in Neurosci., 7:462–464.CrossRefGoogle Scholar
  37. 37.
    Filla, A., Campanella, G., 1982, A six-month phosphatidylcholine trial in Friedreich’s ataxia, Can. J. Neurol. Sci., 9:147–150.PubMedGoogle Scholar
  38. 38.
    Finocchiaro, G., DiDonato, S., Madonna, M., Fusi, R., Ladinsky, H., Consolo, S., 1985, An approach using lecithin treatment for olivopontocerebellar atrophies, Eur. Neurol., 24:414–421.PubMedCrossRefGoogle Scholar
  39. 39.
    Food and Drug Administration Task Force, American College of Neuropsycho-pharmacology, 1973, Neurological syndromes associated with antipsychotic drug use: a special report, Arch. Gen. Psychiatry, 28:463–467.CrossRefGoogle Scholar
  40. 40.
    Friedman E., Sherman, K., Ferris, S.H., Reisberg, B., Bartus, R.T., Schenk, M.K., 1981, Clinical response to choline plus piracetam in senile dementia: relation to red cell choline levels, N. Engl. J. Med., 304:1490–1491.PubMedCrossRefGoogle Scholar
  41. 41.
    Gelenberg, A.J., Doller-Wojcik, J.C., Growdon, J.H., 1979, Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study, Am. J. Psychiatry, 136:772–776.PubMedGoogle Scholar
  42. 42.
    Gibson, G.E., Blass, J.P., 1976, Impaired synthesis of acetylcholine in brain accompanying mild hypoxia and hypoglycemia, J. Neurochem., 27:37–42.PubMedCrossRefGoogle Scholar
  43. 43.
    Growdon, J.H., 1986, Phosphatidylcholine and tardive dyskinesia (letter), Biol. Psychiatry, 21:702–703.PubMedCrossRefGoogle Scholar
  44. 44.
    Growdon, J.H., Cohen, E.L., Wurtman, R.J., 1977, Treatment of brain diseases with dietary precursors of neurotransmitters, Ann. Intern. Med., 86:337–339.PubMedCrossRefGoogle Scholar
  45. 45.
    Growdon, J.H., Cohen, E.L., Wurtman, R.J., 1977, Effects of oral choline administration on serum and CSF choline levels in patients with Huntington’s disease, J. Neurochem., 28:229–231.PubMedCrossRefGoogle Scholar
  46. 46.
    Growdon, J.H., Cohen, E.L., Wurtman, R.J., 1977, Huntington’s disease: clinical and chemical effects of choline administration, Ann. Neurol., 1:418–422.PubMedCrossRefGoogle Scholar
  47. 47.
    Growdon, J.H., Corkin, S., 1979, Neurochemical approaches to the treatment of senile dementia, in.:“Psychopathology in the Aged”, J.O. Cole, J. Barrett, eds., Raven Press, New York, pp. 281–294.Google Scholar
  48. 48.
    Growdon, J.H., Corkin, S., in press, Cognitive impairments in Parkinson’s disease, in:“Parkinson’s Disease (Advances in Neurology series)”, M.D. Yahr, R.C. Duvoisin, eds., Raven Press, New York.Google Scholar
  49. 49.
    Growdon, J.H., Corkin, S., Huff, F.J., Rosen, T.J., 1986, Piracetam combined with lecithin in the treatment of Alzheimer’s disease, Neurobiol. Aging, 7:269–276.PubMedCrossRefGoogle Scholar
  50. 50.
    Growdon, J.H., Gelenberg, A.J., Doller, J., Hirsch, M.J., Wurtman, R.J., 1978, Lecithin can suppress tardive dyskinesia. N. Engl. J. Med., 298:1029–1030.PubMedGoogle Scholar
  51. 51.
    Growdon, J.H., Gibson, C.J., 1982, Dietary precursors of neurotransmitters: treatment strategies, in:“Current Neurology”, S.H. Appel, ed., Wiley and Sons, New York, pp. 117–144.Google Scholar
  52. 52.
    Growdon, J.H., Hirsch, M.J., Wurtman, R.J., Weiner, W., 1977, Oral choline administration to patients with tardive dyskinesia, N. Engl. J. Med., 297:524–527.PubMedCrossRefGoogle Scholar
  53. 53.
    Growdon, J.H., Wheeler, S., Graham, H.N., 1984, Plasma choline responses to lecithin-enriched soup, Psychopharmacol. Bull., 20:603–606.PubMedGoogle Scholar
  54. 54.
    Growdon, J.H., Wurtman, R.J., 1983, The future of cholinergic precursor treatment in Alzheimer’s disease, in:“Banbury Report 15: Biological Aspect of Alzheimer’s Disease”, L. Moran, ed., Banbury Center, Cold Spring Laboratory, pp. 451–459.Google Scholar
  55. 55.
    Haubrich, D.R., Wang, P.F.L., Clody, D.E., Wedeking, P.W., 1975, Increases in rat brain acetylcholine induced by choline or deanol, Life Sci., 17:975–980.PubMedCrossRefGoogle Scholar
  56. 56.
    Hegner, D., 1980, Age dependence of molecular and functional changes in biological membrane properties, Mech. Aging Develop., 14:101–118.CrossRefGoogle Scholar
  57. 57.
    Hirata, F., Axelrod, J., 1978, Enzymatic methylation of phosphatidylethanolamine increases erythrocyte membrane fluidity, Nature, 275:219–220.PubMedCrossRefGoogle Scholar
  58. 58.
    Hirata, F., Axelrod, J., 1980, Phospholipid methylation and biological signal transmission, Science, 209:1082–1090.PubMedCrossRefGoogle Scholar
  59. 59.
    Hirsch, M.J., Growdon, J.H., Wurtman, R.J., 1977, Increase in hippocampal acetylcholine after choline administration, Brain Res., 125:383–385.PubMedCrossRefGoogle Scholar
  60. 60.
    Hirsch, M.J., Wurtman, R.J., 1978, Lecithin comsumption elevates acetylcholine concentrations in rat brain and adrenal gland, Science, 207:223–225.CrossRefGoogle Scholar
  61. 61.
    Hitzemann, R., Hirschowitz, J., Garver, D., 1984, Membrane abnormalities in the psychoses and affective disorders, J. Psychiatr. Res., 18:319–326.PubMedCrossRefGoogle Scholar
  62. 62.
    Hitzemann, R., Mark, C., Hirschowitz, J., Garver, D., 1985, Characteristics of pohspholipid methylation in human erythrocyte ghosts: relationship(s) to the psychoses and affective disorders, Biol. Psychiatry, 20:397–407.PubMedCrossRefGoogle Scholar
  63. 63.
    Hornykiewicz, O., 1982, Brain neurotransmitter changes in Parkinson’s disease, in:“Movement Disorders”, C.D. Marsden, S. Fahn, eds., Butterworth Scientific, London, pp. 41–58.Google Scholar
  64. 64.
    Iida, H., Takashima, Y., Maeda, S., Sekiya, T., Kawade, M., Kawamura, M., Okano, Y., Nozawa, Y., 1984, Alterations in erythrocyte membrane lipids in abetalipoproteinemia: phospholipid and fatty acyl composition, Biochem. Med., 32:79–87.PubMedCrossRefGoogle Scholar
  65. 65.
    Infante, J.P., 1986, Defective synthesis of polyunsaturated phosphatidylcholines as the primary lesion in Duchenne and murine dy muscular dystrophies, Med. Hypotheses, 19:113–116.PubMedCrossRefGoogle Scholar
  66. 66.
    Ishi, T., 1966, Distribution of Alzheimer’s neurofibrillary changes in the brainstem and hypothalamus of senile dementia, Acta Neurol. Pathol, 6:181–187.CrossRefGoogle Scholar
  67. 67.
    Jackson, I.V., Nuttall, E.A., Ibe, I.O., Perez-Cruet, J., 1979, Treatment of tardive dyskinesia with lecithin, Am. J. Psychiatry, 136:1458–1460.PubMedGoogle Scholar
  68. 68.
    Jenike, M.A., Albert, M.S., Heller, H., LoCastro, S., Günther, J., 1986, Combination therapy with lecithin and ergoloid mesylates for Alzheimer’s disease, J. Clin. Psychiatry, 47:249–251.PubMedGoogle Scholar
  69. 69.
    Janowsky, D.S., El-Yousef, M.K., Davis, J.M., Hubbard, H., Sekerke, H.J., 1972, Cholinergic reversal of manic symptoms, Lancet, 1:1236–1237.PubMedCrossRefGoogle Scholar
  70. 70.
    Janowsky, D.S., El-Yousef, K., Davis, J.M., Sekerke, H.J., 1973, Parasympathetic suppression of manic symptoms by physostigmine, Arch. Gen. Psychiatry, 28:542–547.PubMedCrossRefGoogle Scholar
  71. 71.
    Jenden, D.J., Weiler, M.H., Gundersen, C.B., 1982, Choline availability and acetylcholine synthesis, in: “Alzheimer’s Disease: A Report of Progress in Research”, S. Corkin, K.L. Davis, J.H. Growdon, et al., eds., Raven Press, New York, pp. 315–326.Google Scholar
  72. 72.
    Jones, F.D., Mass, J.W., Dekirmenjian, H., et al., 1975, Diagnostic subgroups of affective disorders and their urinary excretion of catecholamine metabolites, Am. J. Psychiatry, 132:1141–1148.Google Scholar
  73. 73.
    Kane, J.M., Woerner, M., Borenstein, M., Wegner, J., Lieberman, J., 1986, Integrating incidence and prevalence of tardive dyskinesia, Psychopharmacol. Bull., 22:254–258.PubMedGoogle Scholar
  74. 74.
    Kark, P.A., Blass, J., Spence, M.A., 1977, Physostigmine in familial ataxias, Neurology, 27:70–72.PubMedCrossRefGoogle Scholar
  75. 75.
    Kaye, W.H., Sitaram, N., Weingartner, H., Ebert, M.H., Smallberg, S., Gillin, J.C., 1982, Modest facilitation on memory in dementia with combined lecithin and anticholinesterase treatment, Biol. Psychiatry, 17:275–280.PubMedGoogle Scholar
  76. 76.
    Kelemen, J., Hedlund, W., Murray-Douglas, P., Munsat, T.L., 1982, Lecithin is not effective in amyotrophic lateral sclerosis, Neurology, 32:315–316.PubMedCrossRefGoogle Scholar
  77. 77.
    Klawans, H.L., Jr., Rubovits, R., 1972, Central cholinergic-anticholinergic antagonism in Huntington’s chorea, Neurology, 22:107–112.PubMedCrossRefGoogle Scholar
  78. 78.
    Kunze, D., Rustow, B., Kuksis, A., Myher, J.J., 1986, Acylation of lysophosphatidylcholine and glycerolphosphate and fatty acid pattern in phosphatidylcholine and ethanolamine in microsomes of normal and dystrophic human muscle, Acta Neurol. Scand., 73:125–130.PubMedCrossRefGoogle Scholar
  79. 79.
    LaDroitte, P., Lamboeuf, Y., de Saint Blanquat, G., Bezaury, J.P., 1985, Sensitivity of individual erythrocyte membrane phospholipids to changes in fatty acid composition in chronic alcoholic patients, Alcoholism (NY), 9:135–137.CrossRefGoogle Scholar
  80. 80.
    Lawrence, G.M., Millac, P., Stout, G.S., et al., 1980, The use of choline chloride in ataxic disorders, J. Neurol. Neurosurg., Psychiatry, 43:452–545.CrossRefGoogle Scholar
  81. 81.
    Legg, N.J., 1978, Oral choline in cerebellar ataxia, Br. Med. J., 2:1403–1404.PubMedCrossRefGoogle Scholar
  82. 82.
    Little, A., Levy, R., Chuaqui-Kidd, P., Hand, D., 1985, A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer’s disease, J. Neurol. Neurosurg., Psychiatry, 48:736–742.CrossRefGoogle Scholar
  83. 83.
    Livingstone, I.R., Mastaglia, F.L., 1979, Choline chloride in the treatment of ataxia, Br. Med. J., 2:939.PubMedCrossRefGoogle Scholar
  84. 84.
    London, E.D., Coyle, J.T., 1978, Pharmacological augmentation of acetylcholine levels in kainate lesioned rat striatum, Biochem. Pharmacol., 27:2962–2965.PubMedCrossRefGoogle Scholar
  85. 85.
    Maas, J.W., 1975, Biogenic amines and depression — biochemical and pharmacological separation of two types of depression, Arch. Gen. Psychiatry, 32:1357–1361.PubMedCrossRefGoogle Scholar
  86. 86.
    Mann, D.M.A., Lincoln, J., Yates, P.D., et al., 1980, Changes in monoamine containing neurons of the human CNS in senile dementia, Brit. J. Psychiatry, 136:533–541.CrossRefGoogle Scholar
  87. 87.
    Martin, J.B., 1984, Huntington’s disease: new approaches to an old problem, Neurology, 34:1059–1072.PubMedCrossRefGoogle Scholar
  88. 88.
    Miatto O., Gonzalez, R.G., Buonanno, F., Growdon, J.H., in press, In vitro 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer’s disease, Can. J. Neurol. Sci.Google Scholar
  89. 89.
    Mizumori, S.J.Y., Patterson, T.A., Sternberg, H., Rosenzweig, M.R., Bennett, E.L., Timiras, P.S., 1985, Effects of dietary choline on memory and brain chmistry in aged mice, Neurobiol. of Aging, 6:51–56.CrossRefGoogle Scholar
  90. 90.
    McGeer, P.L., McGeer, E.G., Fibiger, H.C., 1973, Choline acetylase and glutamic acid decarboxylase in Huntington’s chorea, Neurology, 23:912–917.PubMedCrossRefGoogle Scholar
  91. 91.
    Moldofsky, H., Sandor, P., 1983, Lecithin in the treatmen of Gilles de la Tourette’s syndrome, Am. J. Psychiatry, 140:1627–1629.PubMedGoogle Scholar
  92. 92.
    Newhouse, P., Bridenbaugh, R.H., 1981, Pharmacologic characterization and lecithin treatment of a patient with spontaneous oral-facial dyskinesia and dementia. Am. J. Psychiatry, 138:251–252.PubMedGoogle Scholar
  93. 93.
    Papavasiliou, P.S., Rosal, V., 1979, Effects of choline in patients with levodopa-induced dyskinesia, in: “Choline and Lecithin in Brain Disorders”, A. Barbeau, J.H. Growdon, R.J. Wurtman, eds., Raven Press, New York, pp. 335–341.Google Scholar
  94. 94.
    Pentland, B., Martyn, C.N., Steer, C.R., Christie, J.E., 1981, Lecithin treatment in Friedreich’s ataxia, Br. Med. J. (Clin. Res.), 282:1197–1198.CrossRefGoogle Scholar
  95. 95.
    Perez-Cruet, J., Menendez, I., Alvarez-Ghersi, J., Falcon, J.R., Valderrabano, O., Castro-Urrutia, E.C., Ifarraguerri, C., Perez, L.L., 1981, Double-blind study of lecithin in the treatment of persistent tardive dyskinesia. Bol. Assoc. Med. PR, 73:531–537.Google Scholar
  96. 96.
    Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.M., Perry, R.H., 1978, Correlation of cholinergic abnormalities with senile plaques and mental scores in senile dementia, Brit. Med. J., 2:1457–1459.PubMedCrossRefGoogle Scholar
  97. 97.
    Peters, B.H., Levin, H.S., 1979, Effects of physostigmine and lecithin on memory in Alzheimer’s disease, Ann. Neurol., 6:219–221.PubMedCrossRefGoogle Scholar
  98. 98.
    Pettegrew, J.W., Minshew, N.J., Cohen, M.M., Kopp, S.J., Glonek, T., 1984, 31-P changes in Alzheimer’s and Huntington’s disease brain, Neurology, 34:281.Google Scholar
  99. 99.
    Pettegrew J.W., Minshew, N., Glonek, T., Kopp, S., Cohen, M., 1982, 31-P nuclear magnetic resonance analysis of Huntington and control brain, Neurology, 32:196.CrossRefGoogle Scholar
  100. 100.
    Pettegrew, J.W., Minshew, N.J., Diehl, J., Smith, T., Kopp, S.J., Glonek, T., 1983, Anatomical considerations for interpreting topical P-31 NMR, Lancet, ii, 913.CrossRefGoogle Scholar
  101. 101.
    Philcox, D.V., Kies, B., 1979, Choline in hereditary ataxia, Brit. Med. J., 2:613.PubMedCrossRefGoogle Scholar
  102. 102.
    Pirozzolo, F.J., Hansch, E.C., Mortimer, J.A., Webster, D.D., Kuskowski, M.A., 1982, Dementia in Parkinson’s disease: a neuropsychological analysis, Brain and Cognition, 1:71–83.PubMedCrossRefGoogle Scholar
  103. 103.
    Polinsky, R.J., Ebert, M.H., Caine, E.D., Ludlow, C., Bassich, C.J., 1980, Cholinergic treatment in the Tourette syndrome, N. Engl. J. Med., 302:1310.PubMedCrossRefGoogle Scholar
  104. 104.
    Randels, P.M., Marco, L.A., Ford, D.I., Mitchell, R., Scholl, M., Plesnarski, J., 1984, Lithium and lecithin treatment in Alzheimer’s disease: a pilot study, Hillside J. Clin. Psychiatry, 6:139–147.PubMedGoogle Scholar
  105. 105.
    Reding, M.J., Blass, J.P., Stern, P.H., et al., 1981, Lecithin in hereditary ataxia, Neurology, 31:363–364.PubMedCrossRefGoogle Scholar
  106. 106.
    Richardson, M.A., Craig, T.J., Branchey, M.H., 1982, Intra-patient variability in the measurement of tardive dyskinesia, Psychopharmacology (Berlin), 76:269–272.CrossRefGoogle Scholar
  107. 107.
    Scheife, R.T., Growdon, J.H., 1982, Treating tardive dyskinesia, Seminars in Neurology, 2:305–315.CrossRefGoogle Scholar
  108. 108.
    Schildkraut, J.J., 1965, The catecholamine hypothesis of affective disorders: a review of supporting evidence, Am. J. Psychiatry, 122:509–522.PubMedGoogle Scholar
  109. 109.
    Schildkraut, J.J., Orsulak, P.J., Schatzberg, A.F., et al., 1978, Toward a biochemical classification of depressive disorders, Part I, Arch. Gen. Psychiatry, 35:1427–1433.PubMedCrossRefGoogle Scholar
  110. 110.
    Schreier, H.A., 1982, Mania responsive to lecithin in a 13-year-old girl, Am. J. Psychiatry, 139:108–110.PubMedGoogle Scholar
  111. 111.
    Smith, R.C., Vroulis, G., Johnson, R., Morgan, R., 1984, Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer’s disease, Psychopharmacol. Bull., 20:542–545.PubMedGoogle Scholar
  112. 112.
    Stahl, S.M., Berger, P.A., 1980, Cholinergic treatment in the Tourette syndrome, N. Engl. J. Med., 302:1311.CrossRefGoogle Scholar
  113. 113.
    Tamminga, C.A., Smith, R.C., Erickson, S.E., et al., 1977, Cholinergic influences in tardive dyskinesia, Am. J. Psychiatry, 134:769–774.PubMedGoogle Scholar
  114. 114.
    Tanner, C.M., Goetz, C.G., Klawans, H.L., 1982, Cholinergic mechanisms in Tourette syndrome, Neurology, 32:1315–1317.PubMedCrossRefGoogle Scholar
  115. 115.
    Terry, R.D., Peck, A., DeTeresa, R., Schechter, R, Horoupian, D.S., 1981, Some morphometric aspects of the brain in senile dementia of the Alzheimer type, Ann. Neurol., 10:184–192.Google Scholar
  116. 116.
    Thal, L.J., Fuld, P.A., Masur, D.M., Sharpless, N.S., 1983, Oral physostigmine and lecithin improve memory in Alzheimer’s disease, Ann. Neurol., 13:491–496.PubMedCrossRefGoogle Scholar
  117. 117.
    Tweedy, J.R., Garcia, CA., 1982, Lecithin treatment of cognitively impaired Parkinson’s patients, Eur. J. Clin. Invest., 12:87–90.PubMedCrossRefGoogle Scholar
  118. 118.
    Ulus, I.H., Hirsch, M.J., Wurtman, R.J., 1977, Trans-synaptic induction of adrenal tyrosine hydroxylase activity by choline: evidence that choline administration increases cholinergic transmission, Proc. Natl. Acad. Sci. USA., 74:798–800.PubMedCrossRefGoogle Scholar
  119. 119.
    Wecker, L., Dettbarn, W.D., Schmidt, E.D., 1978, Choline administration: modification of the central actions of atropine, Science, 199:86–87.PubMedCrossRefGoogle Scholar
  120. 120.
    Wettstein, A., 1983, No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease, Ann. Neurol., 13:210–212.PubMedCrossRefGoogle Scholar
  121. 121.
    Whitehouse, P.J., Price, D.L., Coyle, J.T., DeLong, M.R., 1981, Alzheimer’s disease: evidence for selective loss of cholinergic neurons in the nucleus basalis, Ann. Neurol., 10:122–126.PubMedCrossRefGoogle Scholar
  122. 122.
    Wilcock, G.K., Esiri, M.M., Bowen, D.M., Smith, C.C.T., 1982, Alzheimer’s disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities, J. Neurol. Sci., 57:407–417.PubMedCrossRefGoogle Scholar
  123. 123.
    Wurtman, R.J., Blusztajn, J.K., Maire, J.C., 1985, “Autocannibalism” of choline-containing membrane phospholipids in the pathogenesis of Alzheimer’s disease — a hypothesis, Neurochem. Int., 7:369–372.PubMedCrossRefGoogle Scholar
  124. 124.
    Wurtman, R.J., Hirsch, M.J., Growdon, J.H., 1977, Lecithin consumption raises serum free choline levels, Lancet, 2:68–69.PubMedCrossRefGoogle Scholar
  125. 125.
    Yackulic, C.F., Anderson, B.G., Reker, D., Webb, E., Volavka, J., 1982, The safety of lecithin diet supplementation in schizophrenic patients, Biol. Psychiatry, 17:1445–1448.PubMedGoogle Scholar
  126. 126.
    Zeisel, S.H., Growdon, J.H., Wurtman, R.J., Magil, S.G., Logue, M., 1980, Normal plasma choline responses to ingested lecithin, Neurology, 30:1226–1229.PubMedCrossRefGoogle Scholar
  127. 127.
    Zubenko, G.S., Cohen, B.M., Growdon, J.H., Corkin, S., 1984, Cell membrane abnormality in patients with Alzheimer’s disease, Lancet, 2:235.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • John H. Growdon
    • 1
  1. 1.Department of NeurologyMassachusetts General HospitalBostonUSA

Personalised recommendations